Disagreement between the results from three commercial tests for the detection of Borrelia-specific serum antibodies in the Netherlands associated with antibiotic treatment for Lyme borreliosis: a retrospective study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
TitleDisagreement between the results from three commercial tests for the detection of Borrelia-specific serum antibodies in the Netherlands associated with antibiotic treatment for Lyme borreliosis: a retrospective study.
Published inEur J Clin Microbiol Infect Dis 2017, 36(11):2137-46
PubliekssamenvattingThe diagnosis of Lyme borreliosis is challenging because of the often non-specific symptoms and persisting antibodies after infection. We investigated the diagnostic characteristics of two enzyme-linked immunosorbent assays (ELISAs) and an immunoblot for the detection of Borrelia-specific serum antibodies using different test strategies in individuals with and without antibiotic treatment for Lyme borreliosis. This retrospective study included healthy individuals, patients with active Lyme neuroborreliosis and patients treated for Lyme neuroborreliosis. Two ELISAs were compared: the C6 ELISA and the SERION ELISA. Equivocal and positive results were confirmed by immunoblot. We included 174 healthy individuals, of whom 27 (15.5%) were treated for Lyme borreliosis in the past, 36 patients were treated for Lyme neuroborreliosis and 27 patients had active Lyme neuroborreliosis. All the active Lyme neuroborreliosis patients were reactive in both ELISAs (100% sensitivity); less reactivity was seen in the other three groups (range 17.7% to 69.4%). The concordance between the ELISA results was high in active Lyme neuroborreliosis patients (26/27; 96.3%) and healthy individuals (131/147; 89.1%), but lower in treated healthy individuals (18/27; 66.7%) and treated Lyme neuroborreliosis patients (18/36; 50.0%) (p ≤ 0.005). This study showed that antibiotic treatment against Lyme borreliosis was strongly associated with discordant ELISA and test strategy results (odds ratio: 10.52; p < 0.001 and 9.98; p = 0.014, respectively) suggesting antibiotic treatment influences the pace at which the various antibodies directed to the different antigens used in both ELISAs wane. Among treated neuroborreliosis patients, the SERION ELISA stayed positive for a longer period after infection compared to the C6 ELISA. This should be taken into consideration when requesting and/or interpreting Lyme serology.
- Predictive value of Borrelia burgdorferi IgG antibody levels in patients referred to a tertiary Lyme centre.
- Authors: Zwerink M, Zomer TP, van Kooten B, Blaauw G, van Bemmel T, van Hees BC, Vermeeren YM, Landman GW
- Issue date: 2018 Mar
- Recombinant immunoblot in the serodiagnosis of Lyme borreliosis. Comparison with indirect immunofluorescence and enzyme-linked immunosorbent assay.
- Authors: Wilske B, Fingerle V, Herzer P, Hofmann A, Lehnert G, Peters H, Pfister HW, Preac-Mursic V, Soutschek E, Weber K
- Issue date: 1993 Nov
- Serological Evidence of Borrelia Burgdorferi Infection in Mexican Patients with Facial Palsy.
- Authors: Gordillo-Pérez G, García-Juárez I, Solórzano-Santos F, Corrales-Zúñiga L, Muñoz-Hernández O, Torres-López J
- Issue date: 2017 Nov-Dec
- Evaluation of Selected Borrelia burgdorferi lp54 Plasmid-Encoded Gene Products Expressed during Mammalian Infection as Antigens To Improve Serodiagnostic Testing for Early Lyme Disease.
- Authors: Weiner ZP, Crew RM, Brandt KS, Ullmann AJ, Schriefer ME, Molins CR, Gilmore RD
- Issue date: 2015 Nov
- [Clinical forms of neuroborreliosis among hospitalized patients in the years 2000-2005].
- Authors: Czupryna P, Kuśmierczyk J, Zajkowska JM, Ciemerych M, Kondrusik M, Ciemerych A, Pancewicz SA
- Issue date: 2007 Aug